<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA"/></p>
<p>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - 获取免费报告) 在五月份看到了空头头寸大幅下降。截至 5 月 15 日，空头头寸总计为 37.2 万股，较 4 月 30 日的 41.45 万股下降了 10.3%。目前，公司股票中有 1.3% 被做空。根据平均每日交易量为 18.53 万股，目前的天数覆盖率为 2.0 天。</p>
<p>获取 <strong>Werewolf Therapeutics</strong> 警报：</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近买入并出售了该公司的股票。Financial Perspectives Inc 在第四季度增加了对 Werewolf Therapeutics 的持仓 80.0%。Financial Perspectives Inc 现在拥有该公司价值 26,000 美元的 6,750 股股票，在上个季度期间增持了 3,000 股。Certuity LLC 在第四季度新建了一份价值 39,000 美元的 Werewolf Therapeutics 头寸。Lighthouse Investment Partners LLC 在第四季度新建了一份价值 87,000 美元的 Werewolf Therapeutics 头寸。Denali Advisors LLC 在第一季度新建了一份价值 17.2 万美元的 Werewolf Therapeutics 头寸。最后，Acadian Asset Management LLC 在第一季度增加了对 Werewolf Therapeutics 的持仓 119.8%。Acadian Asset Management LLC 现在拥有该公司价值 111.9 万美元的 17.28 万股股票，在上个季度期间增持了 9.42 万股。机构投资者和对冲基金拥有该公司股票的 64.84%。</p>
<h2>Werewolf Therapeutics 股价下跌 22.8%</h2>
<p>NASDAQ:HOWL 周一交易时下跌 1.18 美元，至 3.99 美元。该公司股票的交易量为 40.95 万股，相比平均交易量 22.46 万股有所增加。该公司的市值为 1.7341 亿美元，市盈率为-4.00，贝塔系数为 0.62。Werewolf Therapeutics 一年内最低为 1.57 美元，最高为 8.19 美元。该公司的 50 天移动平均价为 5.62 美元，200 天移动平均价为 5.06 美元。该公司的资产负债比为 0.24，流动比率为 6.71，速动比率为 6.71。</p>
<p>Werewolf Therapeutics (NASDAQ:HOWL - 获取免费报告) 上次发布季度财报是在 5 月 3 日星期五。该公司报告该季度每股收益为（0.39）美元，低于分析师预期的（0.35）美元。该季度业务收入为 740 万美元，低于预期的 500 万美元。Werewolf Therapeutics 的净资产回报率为-36.15%，净利润率为-256.33%。股票研究分析师预测，Werewolf Therapeutics 今年将发布-1.52 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<p>多位分析师发布了关于 HOWL 股票的报告。Wedbush 在 5 月 6 日星期一的研究报告中重申了 “跑赢市场” 评级，并设定了 9.00 美元的目标价。HC Wainwright 在周一重申了 “买入” 评级，并设定了 15.00 美元的目标价。最后，JMP Securities 在 5 月 6 日星期一的报告中重申了 “市场跑赢” 评级，并设定了 12.00 美元的目标价。</p>
<p><strong>查看我们对 Werewolf Therapeutics 的最新分析</strong></p>
<h2>Werewolf Therapeutics 公司简介（获取免费报告）</h2>
<p>Werewolf Therapeutics, Inc 是一家生物制药公司，开发旨在刺激人体免疫系统以治疗癌症的治疗药物。该公司通过其专有的 PREDATOR 平台设计条件激活分子，刺激适应性和先天免疫，以解决传统促炎免疫疗法的局限性。</p>
<h2>阅读更多</h2>
<ul>
<li>我们喜欢的五支股票胜过 Werewolf Therapeutics</li>
<li>如何投资小市值股票</li>
<li>为什么 Smartsheet 股票是被低估的投资宝石</li>
<li>股票平均计算器</li>
<li>Q1 季度财报后最受看好的股票</li>
<li>最佳 ESG 股票：ESG 投资的 11 支最佳股票</li>
<li>什么是风险承受能力，为什么重要？</li>
</ul>
<p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 石油美元的崩溃（来自 Colonial Metals）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjEy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjEy"/></p>
<h2>现在是否值得投资 1,000 美元到 Werewolf Therapeutics？</h2>
<p>在考虑投资 Werewolf Therapeutics 之前，您会想要听到这个。</p>
<p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Werewolf Therapeutics 不在名单上。</p>
<p>虽然 Werewolf Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

HOWL

<p>Werewolf Therapeutics, Inc.（纳斯达克股票代码：HOWL）在五月份经历了空头头寸的显著下降，较上个月减少了 10.3%。该公司的股票空头头寸为 1.3%，覆盖天数比率为 2.0。该公司本季度的财务表现显示出负的净资产回报率和负的净利润率。分析师们对 Werewolf Therapeutics 发表了各种评级</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg/query-dj0yMDIzMDEwMzE1MTgyOA" alt="" original-src="https://www.marketbeat.com/logos/werewolf-therapeutics-inc-logo-1200x675.jpg?v=20230103151828"/></p>
<p>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 372,000 shares, a decline of 10.3% from the April 30th total of 414,500 shares. Currently, 1.3% of the company's stock are short sold. Based on an average daily volume of 185,300 shares, the days-to-cover ratio is currently 2.0 days.</p>
<div class="lb-trans"><p>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - 获取免费报告) 在五月份看到了空头头寸大幅下降。截至 5 月 15 日，空头头寸总计为 37.2 万股，较 4 月 30 日的 41.45 万股下降了 10.3%。目前，公司股票中有 1.3% 被做空。根据平均每日交易量为 18.53 万股，目前的天数覆盖率为 2.0 天。</p>
</div><p>Get <strong>Werewolf Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Werewolf Therapeutics</strong> 警报：</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. Financial Perspectives Inc lifted its position in Werewolf Therapeutics by 80.0% during the 4th quarter. Financial Perspectives Inc now owns 6,750 shares of the company's stock worth $26,000 after acquiring an additional 3,000 shares during the last quarter. Certuity LLC acquired a new position in Werewolf Therapeutics during the 4th quarter worth $39,000. Lighthouse Investment Partners LLC acquired a new position in Werewolf Therapeutics during the 4th quarter worth $87,000. Denali Advisors LLC acquired a new position in Werewolf Therapeutics during the 1st quarter worth $172,000. Finally, Acadian Asset Management LLC lifted its position in Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company's stock worth $1,119,000 after acquiring an additional 94,212 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买入并出售了该公司的股票。Financial Perspectives Inc 在第四季度增加了对 Werewolf Therapeutics 的持仓 80.0%。Financial Perspectives Inc 现在拥有该公司价值 26,000 美元的 6,750 股股票，在上个季度期间增持了 3,000 股。Certuity LLC 在第四季度新建了一份价值 39,000 美元的 Werewolf Therapeutics 头寸。Lighthouse Investment Partners LLC 在第四季度新建了一份价值 87,000 美元的 Werewolf Therapeutics 头寸。Denali Advisors LLC 在第一季度新建了一份价值 17.2 万美元的 Werewolf Therapeutics 头寸。最后，Acadian Asset Management LLC 在第一季度增加了对 Werewolf Therapeutics 的持仓 119.8%。Acadian Asset Management LLC 现在拥有该公司价值 111.9 万美元的 17.28 万股股票，在上个季度期间增持了 9.42 万股。机构投资者和对冲基金拥有该公司股票的 64.84%。</p>
</div><h2>Werewolf Therapeutics Stock Down 22.8 %</h2>
<div class="lb-trans"><h2>Werewolf Therapeutics 股价下跌 22.8%</h2>
</div><p>NASDAQ:HOWL traded down $1.18 during trading hours on Monday, reaching $3.99. The company's stock had a trading volume of 409,564 shares, compared to its average volume of 224,620. The company has a market cap of $173.41 million, a price-to-earnings ratio of -4.00 and a beta of 0.62. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19. The business's 50-day moving average is $5.62 and its 200-day moving average is $5.06. The company has a debt-to-equity ratio of 0.24, a current ratio of 6.71 and a quick ratio of 6.71.</p>
<div class="lb-trans"><p>NASDAQ:HOWL 周一交易时下跌 1.18 美元，至 3.99 美元。该公司股票的交易量为 40.95 万股，相比平均交易量 22.46 万股有所增加。该公司的市值为 1.7341 亿美元，市盈率为-4.00，贝塔系数为 0.62。Werewolf Therapeutics 一年内最低为 1.57 美元，最高为 8.19 美元。该公司的 50 天移动平均价为 5.62 美元，200 天移动平均价为 5.06 美元。该公司的资产负债比为 0.24，流动比率为 6.71，速动比率为 6.71。</p>
</div><p>Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. Equities research analysts predict that Werewolf Therapeutics will post -1.52 EPS for the current year.</p>
<div class="lb-trans"><p>Werewolf Therapeutics (NASDAQ:HOWL - 获取免费报告) 上次发布季度财报是在 5 月 3 日星期五。该公司报告该季度每股收益为（0.39）美元，低于分析师预期的（0.35）美元。该季度业务收入为 740 万美元，低于预期的 500 万美元。Werewolf Therapeutics 的净资产回报率为-36.15%，净利润率为-256.33%。股票研究分析师预测，Werewolf Therapeutics 今年将发布-1.52 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several analysts have issued reports on HOWL shares. Wedbush reissued an &#34;outperform&#34; rating and set a $9.00 target price on shares of Werewolf Therapeutics in a research note on Monday, May 6th. HC Wainwright restated a &#34;buy&#34; rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Monday. Finally, JMP Securities restated a &#34;market outperform&#34; rating and set a $12.00 price target on shares of Werewolf Therapeutics in a report on Monday, May 6th.</p>
<div class="lb-trans"><p>多位分析师发布了关于 HOWL 股票的报告。Wedbush 在 5 月 6 日星期一的研究报告中重申了 “跑赢市场” 评级，并设定了 9.00 美元的目标价。HC Wainwright 在周一重申了 “买入” 评级，并设定了 15.00 美元的目标价。最后，JMP Securities 在 5 月 6 日星期一的报告中重申了 “市场跑赢” 评级，并设定了 12.00 美元的目标价。</p>
</div><p><strong>View Our Latest Analysis on Werewolf Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Werewolf Therapeutics 的最新分析</strong></p>
</div><h2>Werewolf Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Werewolf Therapeutics 公司简介（获取免费报告）</h2>
</div><p>Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.</p>
<div class="lb-trans"><p>Werewolf Therapeutics, Inc 是一家生物制药公司，开发旨在刺激人体免疫系统以治疗癌症的治疗药物。该公司通过其专有的 PREDATOR 平台设计条件激活分子，刺激适应性和先天免疫，以解决传统促炎免疫疗法的局限性。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Werewolf Therapeutics</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Why Smartsheet Stock is an Undervalued Gem of an Investment</li>
<li>Stock Average Calculator</li>
<li>The Most Upgraded Stocks After the Q1 Earnings Season</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>What Is Risk Tolerance &amp; Why Is It Important?</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>我们喜欢的五支股票胜过 Werewolf Therapeutics</li>
<li>如何投资小市值股票</li>
<li>为什么 Smartsheet 股票是被低估的投资宝石</li>
<li>股票平均计算器</li>
<li>Q1 季度财报后最受看好的股票</li>
<li>最佳 ESG 股票：ESG 投资的 11 支最佳股票</li>
<li>什么是风险承受能力，为什么重要？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 Narrative Science 技术和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Collapse of the Petrodollar (From Colonial Metals)(Ad)</p>
<div class="lb-trans"><p>→ 石油美元的崩溃（来自 Colonial Metals）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MjEy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8212&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Werewolf Therapeutics right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元到 Werewolf Therapeutics？</h2>
</div><p>Before you consider Werewolf Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Werewolf Therapeutics 之前，您会想要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Werewolf Therapeutics 不在名单上。</p>
</div><p>While Werewolf Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Werewolf Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Werewolf Therapeutics, Inc.（NASDAQ:HOWL）空头头寸大幅减少